Abstract
We evaluated the toxicity of high-dose local interleukin-2 (IL-2) in 18 patients not eligible for standard treatment of advanced transitional cell bladder carcinoma. Seven received continuous high-dose local natural IL-2 via pump system in the bladder for up to 420 days. 11 received cyclic high-dose local natural IL-2 or recombinant IL-2 for up to 420 days. Treatment was well tolerated and, considering the low rate of toxicity, could be offered in an outpatient setting. Except for local contrast-media hypersensitivity, no serious side-effects were observed. This study provides a basis for the non-toxic use of local IL-2 in future studies to evaluate effectiveness of the treatment or prophylaxis of patients with superficial bladder cancer in order to prevent recurrences.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Intravesical
-
Aged
-
Aged, 80 and over
-
Carcinoma, Transitional Cell / blood
-
Carcinoma, Transitional Cell / drug therapy*
-
Carcinoma, Transitional Cell / surgery
-
Combined Modality Therapy
-
Cytokines / blood
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Eosinophils / cytology
-
Eosinophils / drug effects
-
Female
-
Humans
-
Immunity / drug effects
-
Interleukin-2 / administration & dosage*
-
Interleukin-2 / toxicity*
-
Interleukin-2 / urine
-
Leukocyte Count / drug effects
-
Male
-
Middle Aged
-
Perfusion
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / toxicity
-
Recombinant Proteins / urine
-
Urinary Bladder Neoplasms / blood
-
Urinary Bladder Neoplasms / drug therapy*
-
Urinary Bladder Neoplasms / surgery
Substances
-
Cytokines
-
Interleukin-2
-
Recombinant Proteins